Cointime update: Summit Therapeutics said the U.S. Food and Drug Administration issued a Complete Response Letter for its Biologics License Application for ivonescimab combined with platinum-based chemotherapy in previously treated EGFR TKI-treated locally advanced or metastatic non-small cell lung cancer. The FDA action blocks the drug’s U.S. approval for that indication, with overall survival not yet established as a key endpoint.
FDA Issues Complete Response Letter for Summit’s Ivonescimab BLA
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
10m ago
UBS Global Wealth Management Forecasts S&P 500 at 8,200 by End-2027
32m ago
Tencent Q3 2026 Revenue Rises 8% to RMB 207.3 Billion
52m ago
Hong Kong’s Hang Seng closes down 0.91%; Zhipu jumps over 9%
1h ago
JPMorgan Keeps Zhipu at Overweight, HK$1,200 Target
1h ago
Morgan Stanley’s Wilson: Nvidia Q3 Results Broadly In Line, AI Still Worth Investing
2h ago
Nvidia beats estimates; analysts flag lingering uncertainty over outlook